Quantcast

Industry news that matters to you.  Learn more

Imaging Biomarkers

Large pharma has been seeking new biomarkers for years – all part of their drug discovery process, but often only as an afterthought in the development process. That’s changed over recent years, but by-and-large the bulk of biomarker work remains in the hands of small- to medium-sized companies whose focused approach is more attuned to biomarkers being a major element of a final product.

ProxiScan Completes First Animal Tests

The first animal studies made using a 2009 R&D 100 Award-winning technology were recently performed at Molecular Insight Pharmaceuticals (MIP) in Cambridge, Mass. A new small molecule drug, Trofex, was successfully tested for its effectiveness as a biomarker for the detection of prostate cancer.

Pacific Biomarkers Launches New Website

Pacific Biomarkers, Inc., a provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries, unveiled its new website on Friday, July 23. The site, www.PacBio.com, incorporates numerous features to make browsing a more fruitful experience for the Company’s current and potential customers and investors.

New Multiplex Panels from Aushon BioSystems Help Measure Urinary Biomarkers of Kidney Damage during Drug Development

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, has launched new Human multiplex biomarker panels for the quantification of eight biomarkers related to drug-induced kidney damage, or nephrotoxicity. Recent studies identifying biomarkers for kidney injury during pre-clinical testing for certain drugs helped initiate the development of the new panels. Requiring minimal sample volume, the new multiplex biomarker panels address the need for a more rapid, sensitive and accurate method to identify and quantify renal toxicity biomarkers to assist in determining risk.

TGen partner, PBS-Bio, makes first breakthrough drug analysis

Predictive Biomarker Sciences Inc. (PBS-Bio) has completed its first drug analysis, enabling Canadian biotech company PharmaGap Inc. to significantly advance a potentially significant anti-cancer medication.